

# CJC-1295 with DAC — Research Summary

*Research Use Only. Not for human consumption. For laboratory/research reference purposes only.*

*Part of the Prolific Peptides Research Library — a summary of published third-party research, provided for informational and research purposes only. This content is separate from product listings and does not constitute a claim about any Prolific Peptides product's effects.*

## 1. What It Is

CJC-1295 (with Drug Affinity Complex) is a synthetic analog of human growth hormone-releasing hormone (GHRH), modified with amino-acid substitutions for resistance to DPP-IV degradation and conjugated to a maleimidopropionyl-biotin linker that covalently binds circulating albumin after injection.

The albumin conjugation extends plasma half-life to roughly 6–8 days (versus minutes for native GHRH), producing sustained rather than pulsatile GHRH-receptor stimulation. It acts on GHRH receptors (Gs/cAMP/PKA pathway) on anterior pituitary somatotrophs.

## 2. Reported Effects in Research Literature

*Reminder: Research Use Only. Not for human consumption. The following is a summary of published research findings, not a therapeutic claim.*

- Animal data: In GHRH-knockout mice, once-daily to every-72-hour dosing normalized growth, increased pituitary GH mRNA, and increased somatotroph proliferation (Jette et al.; published in AJP-Endocrinology and Metabolism).
- Human data: A 2006 randomized, placebo-controlled, double-blind Phase 1/2 study (Teichman et al., healthy adults ages 21–61) found single subcutaneous doses (1–30 mcg/kg) produced dose-dependent GH increases of 2- to 10-fold sustained 6+ days, and IGF-1 increases of 1.5- to 3-fold sustained 9–11 days.
- Human data: A companion analysis (Ionescu & Frohman, 2006) confirmed that pulsatile GH secretion is preserved even during sustained CJC-1295/DAC stimulation, rather than producing flat continuous elevation.

## 3. Clinical & Preclinical Study References

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683

Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006. PMID: 17018654

Jette L, Leger R, Thibadeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-acting analog. AJP-Endocrinol Metab.

**Regulatory/Safety Note:** No FDA-approved product contains CJC-1295 in any form; it is not available through licensed U.S. compounding pharmacies and has no completed Phase 2/3 efficacy trials.

This compound has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease in humans or animals.

This document is for informational and research purposes only. It does not constitute medical advice, dosing guidance, or an endorsement of human or veterinary use.

For full terms governing research use, see our RUO Policy at ProlificPeptides.com.

This summary may not be reproduced, excerpted, or used as product labeling or marketing copy without written permission from Prolific Peptides, LLC.

Regulatory and research-status information reflects publicly available sources as of September 7, 2026, and may change.